-
公开(公告)号：US20200368513A1
公开(公告)日：2020-11-26
申请号：US16961213
申请日：2019-01-24
Applicant: Bard Peripheral Vascular, Inc.
Inventor： Murtaza Y. Amin
Abstract: Systems and methods for detecting an implanted medical device, such as a vascular access port. The implanted medical device may include at least one passive RFID tag that has disposed thereon information about the implanted medical device. The at least one passive RFID tag is designed to be interrogated by a detector associated with an external device, such as an infusion set with an access needle. The interrogating signal induces a return signal from the at least one passive RFID tags. The strength of the return signal may be dependent on the distance and orientation of the tag relative to the detector. The system may be designed to interpret different signal strengths from different RFID tags to guide the needle to a correct insertion position, thereby accessing a port that cannot be readily detected visually or by palpation.
-
Patent Agency Ranking
公开(公告)号：US11890442B2
公开(公告)日：2024-02-06
申请号：US16961213
申请日：2019-01-24
Applicant: Bard Peripheral Vascular, Inc.
Inventor： Murtaza Y. Amin
CPC classification number: A61M39/0208 , A61M5/14276 , A61M2039/0238 , A61M2205/502 , A61M2205/60
Abstract: Systems and methods for detecting an implanted medical device, such as a vascular access port. The implanted medical device may include at least one passive RFID tag that has disposed thereon information about the implanted medical device. The at least one passive RFID tag is designed to be interrogated by a detector associated with an external device, such as an infusion set with an access needle. The interrogating signal induces a return signal from the at least one passive RFID tags. The strength of the return signal may be dependent on the distance and orientation of the tag relative to the detector. The system may be designed to interpret different signal strengths from different RFID tags to guide the needle to a correct insertion position, thereby accessing a port that cannot be readily detected visually or by palpation.
-
公开(公告)号：US12220510B2
公开(公告)日：2025-02-11
申请号：US17287100
申请日：2019-10-24
Applicant: Bard Peripheral Vascular, Inc.
Inventor： Murtaza Y. Amin , Kevin Wessman
Abstract: An implantable device for treating hypervolemia includes an expandable chamber, a rigid chamber coupled to the expandable chamber, a first valve in fluid communication with both the expandable chamber and the rigid chamber, a second valve in fluid communication with the rigid chamber and an exterior of the implantable device, and an osmotic fluid. The expandable chamber includes a first semipermeable membrane. The rigid chamber includes a piston. The first valve has an open position to permit fluid flow between the expandable chamber and the rigid chamber. The second valve has an open position to permit fluid flow from the rigid chamber to the exterior of the implantable device. The osmotic fluid has a higher osmotic concentration than bodily fluid. The osmotic fluid is designed to absorb water from the bodily fluid through the first semipermeable membrane.
-
公开(公告)号：US12178945B2
公开(公告)日：2024-12-31
申请号：US17287096
申请日：2019-10-24
Applicant: Bard Peripheral Vascular, Inc.
Inventor： Murtaza Y. Amin , Nathan Gooch , Ericka J. Prechtel , Andrew C. Sheffield , Prabir Roy-Chaudhury
Abstract: A catheter (100) for treating hypervolemia in a patient includes a luminal ingress (112) joined to a luminal egress (114) at a distal end portion (116) of the catheter having a closed distal end (102). The distal end portion is configured to at least temporarily reside within a vessel of the patient, the distal end portion including a semipermeable membrane. The luminal ingress is designed to convey an influent having a first osmotic concentration to the distal end portion. The semipermeable membrane is configured to pass blood-borne water from the vessel into the distal portion. The blood-borne water is absorbed by the influent to produce an effluent having a second osmotic concentration lower than the first osmotic concentration. Systems (200) with the catheter and methods for treating hypervolemia are also disclosed.
-
公开(公告)号：US20210393865A1
公开(公告)日：2021-12-23
申请号：US17287100
申请日：2019-10-24
Applicant: Bard Peripheral Vascular, Inc.
Inventor： Murtaza Y. Amin , Kevin Wessman
Abstract: An implantable device for treating hypervolemia includes an expandable chamber, a rigid chamber coupled to the expandable chamber, a first valve in fluid communication with both the expandable chamber and the rigid chamber, a second valve in fluid communication with the rigid chamber and an exterior of the implantable device, and an osmotic fluid. The expandable chamber includes a first semipermeable membrane. The rigid chamber includes a piston. The first valve has an open position to permit fluid flow between the expandable chamber and the rigid chamber. The second valve has an open position to permit fluid flow from the rigid chamber to the exterior of the implantable device. The osmotic fluid has a higher osmotic concentration than bodily fluid. The osmotic fluid is designed to absorb water from the bodily fluid through the first semipermeable membrane.
-
公开(公告)号：US20210386919A1
公开(公告)日：2021-12-16
申请号：US17287096
申请日：2019-10-24
Applicant: Bard Peripheral Vascular, Inc.
Inventor： Murtaza Y. Amin , Nathan Gooch , Ericka J. Prechtel , Andrew C. Sheffield , Prabir Roy-Chaudhury
Abstract: A catheter (100) for treating hypervolemia in a patient includes a luminal ingress (112) joined to a luminal egress (114) at a distal end portion (116) of the catheter having a closed distal end (102). The distal end portion is configured to at least temporarily reside within a vessel of the patient, the distal end portion including a semipermeable membrane. The luminal ingress is designed to convey an influent having a first osmotic concentration to the distal end portion. The semipermeable membrane is configured to pass blood-borne water from the vessel into the distal portion. The blood-borne water is absorbed by the influent to produce an effluent having a second osmotic concentration lower than the first osmotic concentration. Systems (200) with the catheter and methods for treating hypervolemia are also disclosed.
-
-
-
-
-
Search Results
6
records
(took 0.046 seconds)
